Study guide
7.2 Asthma Control Assessment Tools & Validated Questionnaires
Certified Asthma Educator AE-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AE-C Examination 1.2 How to Use This Study Guide
2 Chapter 2: Anatomy, Physiology & Airway Pathophysiology
2.1 Normal vs. Asthmatic Airway Architecture 2.2 Cellular Inflammation, Mediators & Airway Remodeling 2.3 Bronchial Hyperresponsiveness & Airflow Obstruction Mechanics
3 Chapter 3: Triggers, Exposures & Phenotypes
3.1 Aeroallergens & Allergic Sensitization Mechanisms 3.2 Non-Allergic Irritants & Environmental Airborne Hazards 3.3 Respiratory Infections, Exercise & Physiological Stressors 3.4 Asthma Phenotypes, Endotypes & Lifespan Variations 3.5 Genetics, Family History & Early-Life Determinants
4 Chapter 4: Comorbidities, Medications & Asthma Mimics
4.1 Upper Airway Diseases & Gastroesophageal Reflux 4.2 Systemic Comorbidities, Obesity & Adverse Drug Reactions 4.3 Differential Diagnosis & Major Asthma Mimics
5 Chapter 5: Clinical History & Physical Assessment
5.1 Comprehensive Asthma History & Risk Stratification 5.2 Physical Examination, Auscultation & Atopic Stigmata 5.3 Acute Exacerbation Severity Triage & Life-Threatening Red Flags 5.4 Criteria for Specialist Referral & Advanced Consultation 5.5 Medication Reconciliation & Integrating the Medical Record
6 Chapter 6: Diagnostic Testing & Pulmonary Function
6.1 Spirometry Principles, Maneuvers & ATS/ERS Quality Criteria 6.2 Bronchodilator Reversibility Testing Protocols & Interpretation 6.3 Peak Expiratory Flow Monitoring & Personal Best Determination 6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities
7 Chapter 7: Severity, Control & Psychosocial Evaluation
7.1 Asthma Severity Classification (NHLBI EPR-3 & GINA) 7.2 Asthma Control Assessment Tools & Validated Questionnaires 7.3 Health Literacy, Educational Needs Assessment & Plain Language Principles 7.4 Psychosocial, Cultural & Family Dynamics in Self-Management
8 Chapter 8: Reliever Medications & Bronchodilators
8.1 Short-Acting Beta-2 Agonists (SABAs) & Cellular Mechanisms 8.2 SABA Overuse, Paradoxical Hyperresponsiveness & Safety Warnings 8.3 Short-Acting Muscarinic Antagonists (SAMAs) & Acute Adjunctive Therapy 8.4 SMART/MART & Anti-Inflammatory Reliever (AIR) Regimens
9 Chapter 9: Inhaled Corticosteroids & Combination Therapies
9.1 Inhaled Corticosteroids: Pharmacology, Potency & Dosing 9.2 ICS Adverse Effects, Systemic Safety & Dispelling Steroid Phobia 9.3 Long-Acting Beta-2 Agonists & Fixed-Dose Combination Inhalers 9.4 Stepwise Pharmacotherapy Guidelines (Age-Stratified Step-Up & Step-Down)
10 Chapter 10: Additional Controllers & Biologic Therapies
10.1 Leukotriene Modifiers & 5-Lipoxygenase Inhibitors 10.2 Long-Acting Muscarinic Antagonists (LAMAs) & Alternative Controllers 10.3 Monoclonal Antibodies & Biologic Therapies for Severe Asthma 10.4 Systemic Corticosteroids, Adrenal Safety & Immunizations 10.5 Allergen Immunotherapy, Intranasal Therapy & Treating Comorbidities
11 Chapter 11: Inhalation Devices & Delivery Mechanics
11.1 Pressurized Metered-Dose Inhalers (pMDIs) & Valved Holding Chambers 11.2 Dry Powder Inhalers (DPIs): Mechanics, Resistance & Technique 11.3 Soft Mist Inhalers (SMIs) & Small-Volume Nebulizers (SVNs) 11.4 Device Selection Algorithm, Patient Capabilities & Technique Assessment 11.5 Over-the-Counter, Alternative & Complementary Therapies
12 Chapter 12: Environmental Control & Behavioral Interventions
12.1 Evidence-Based Indoor Allergen Mitigation & Integrated Pest Management 12.2 Tobacco Cessation, Electronic Nicotine Systems & Irritant Elimination 12.3 Exercise-Induced Bronchoconstriction (EIB) Management & Sports Participation 12.4 Behavioral Counseling, Motivational Interviewing & Adherence Enhancement 12.5 Social, Economic & Substance-Use Barriers to Self-Management
13 Chapter 13: Action Plans, Exacerbations & Continuing Care
13.1 Written Asthma Action Plans & the Traffic-Light Zone System 13.2 School, Workplace & Childcare Action Plans 13.3 Home & Outpatient Acute Exacerbation Protocols 13.4 Periodic Reevaluation, Step-Down & Post-Discharge Follow-Up 13.5 Designing the Individualized Self-Management Education Plan 13.6 Coaching Decision-Making, Confidence & Documenting Mastery
14 Chapter 14: Program Needs Assessment & Implementation
14.1 Epidemiological Analysis & Community Needs Assessment 14.2 Evidence-Based Asthma Interventions & CDC EXHALE Strategies 14.3 Program Design, Multidisciplinary Staffing & Operational Workflows
15 Chapter 15: Evaluation, Ethics, Quality & Health Systems
15.1 Legal, Ethical, HIPAA/FERPA & Clinical Documentation Standards 15.2 Program Evaluation, CQI Methodologies & Outcome Metrics 15.3 Interprofessional Partnerships, Advocacy & Reimbursement Pathways
7.2 Asthma Control Assessment Tools & Validated Questionnaires
Key Takeaways Explain This Topic AI
Asthma control evaluates the present adequacy of therapeutic management and the degree to which clinical manifestations, functional limitations, and future adverse risks are minimized by current therapy.
The EPR-3 guidelines categorize asthma control into three distinct levels: Well Controlled, Not Well Controlled, and Very Poorly Controlled, utilizing the same dual domains of Impairment (2–4 week recall) and Risk.
The Asthma Control Test (ACT) is a validated 5-item self-administered tool for patients aged ≥12 years with scores ranging from 5 to 25; a score of ≤19 indicates inadequately controlled asthma, and its Minimal Clinically Important Difference (MCID) is 3.0 points.
The Childhood Asthma Control Test (c-ACT) is validated for pediatric patients aged 4 to 11 years, incorporating 4 child-answered pictorial questions (0–3 scale) and 3 parent-answered questions (0–5 scale) for a maximum score of 27, where a score ≤19 defines poorly controlled asthma.
The Asthma Control Questionnaire (ACQ) calculates a mean score on a 0 to 6 scale across symptoms, SABA use, and FEV1; scores ≤0.75 confirm well-controlled asthma, scores ≥1.50 confirm inadequately controlled asthma, and its MCID is 0.5 points.
Last updated: September 2026
7.2 Asthma Control Assessment Tools & Validated Questionnaires
Quick Answer: While asthma severity establishes baseline disease intensity prior to therapy, asthma control evaluates the present adequacy of management once therapy has begun. The NHLBI EPR-3 stratifies control into three categories: Well Controlled, Not Well Controlled, and Very Poorly Controlled . In routine clinical practice, validated standardized questionnaires provide rapid, objective measurement: the Asthma Control Test (ACT) (ages ≥12, scored 5–25, where ≤19 indicates poor control ; MCID = 3.0 points), the Childhood ACT (c-ACT) (ages 4–11, scored 0–27, where ≤19 indicates poor control ), and the Asthma Control Questionnaire (ACQ) (scored 0–6, where ≥1.50 indicates poor control ; MCID = 0.5 points).
Assessing asthma control is the primary operational task during every routine follow-up visit. Uncontrolled asthma is associated with frequent school and work absenteeism, recurrent emergency department visits, progressive airway remodeling, and heightened risk of fatal exacerbations. Because patients frequently underreport symptoms due to chronic habituation—normalizing shortness of breath or subtle activity restriction—certified asthma educators must utilize objective clinical grids and validated numerical questionnaires rather than relying on informal open-ended inquiries such as "How has your breathing been?"
The EPR-3 Asthma Control Framework: Impairment and Risk
The EPR-3 assesses control across the identical dual domains used for severity: Impairment (recalling the prior 2 to 4 weeks) and Risk (evaluating future adverse outcomes). Overall control is assigned based on the most severe category in which any single parameter falls.
Clinical Components of Control Assessment
Daytime Symptoms: Frequency of coughing, wheezing, or dyspnea.
Nighttime Awakenings: Frequency of waking up due to asthma symptoms.
Interference with Normal Activity: Perceived limitation in performing typical physical tasks, work, school, or sports.
SABA Use for Symptom Relief: Frequency of rescue bronchodilator use (excluding pre-exercise prevention).
Pulmonary Function (Ages ≥5 Years): Current FEV1 or peak expiratory flow (PEF) compared against the patient's personal best or predicted normal value.
Risk of Exacerbations: Number of events requiring systemic corticosteroid bursts or hospitalization over the previous year.
Treatment-Related Adverse Effects: Evaluation of local or systemic toxicities from medications (e.g., oral candidiasis, dysphonia, growth deceleration).
EPR-3 Asthma Control Assessment Grid
Age Group Control Level Daytime Symptoms Nighttime Awakenings Activity Interference SABA Use for Relief Lung Function (FEV1 or PEF) Exacerbations Requiring Oral Corticosteroids
≥12 Years & Adults Well Controlled ≤2 days/week ≤2 times/month None ≤2 days/week >80% predicted / personal best 0 to 1 per year
Not Well Controlled >2 days/week 1 to 3 times/week Some limitation >2 days/week 60% to 80% predicted / personal best ≥2 per year
Very Poorly Controlled Throughout the day ≥4 times/week Extremely limited Several times per day <60% predicted / personal best ≥2 per year
5 to 11 Years Well Controlled ≤2 days/week ≤1 time/month None ≤2 days/week >80% predicted / personal best 0 to 1 per year
Not Well Controlled >2 days/week ≥2 times/month Some limitation >2 days/week 60% to 80% predicted / personal best ≥2 per year
Very Poorly Controlled Throughout the day ≥2 times/week Extremely limited Several times per day <60% predicted / personal best ≥2 per year
- 0 to 4 Years Well Controlled ≤2 days/week ≤1 time/month None ≤2 days/week Not Applicable 0 to 1 per year
- Not Well Controlled >2 days/week >1 time/month Some limitation >2 days/week Not Applicable 2 to 3 per year
Very Poorly Controlled Throughout the day >1 time/week Extremely limited Several times per day Not Applicable >3 per year
Validated Asthma Control Questionnaires
To standardize clinical evaluation, researchers have developed numerical self-administered questionnaires. Certified asthma educators must master the structure, target age, scoring metrics, cutoffs, and Minimal Clinically Important Differences (MCID) of each instrument.
1. Asthma Control Test (ACT)
Target Population: Patients aged 12 years and older (adolescents and adults).
Recall Window: Past 4 weeks .
Structure: 5 items evaluated on a 1-to-5 Likert scale:
Interference with work, school, or home tasks.
Frequency of shortness of breath.
Frequency of nighttime awakenings or early morning awakenings.
Frequency of rescue inhaler use.
Patient's overall self-rating of asthma control.
Scoring & Interpretation (Range: 5 to 25):
20 to 25: Well Controlled asthma.
16 to 19: Not Well Controlled asthma.
5 to 15: Very Poorly Controlled asthma.
Validated Cutoff: A score of ≤19 is the internationally recognized threshold indicating poorly or inadequately controlled asthma requiring clinical evaluation.
Minimal Clinically Important Difference (MCID): 3.0 points . A change of 3 or more points reflects a clinically meaningful improvement or deterioration that justifies a change in therapeutic decision-making.
2. Childhood Asthma Control Test (c-ACT)
Target Population: Pediatric patients aged 4 to 11 years .
Recall Window: Past 4 weeks .
Structure (7 Items Total): Combines child-reported perceptions and parent/caregiver observations:
Part 1 (Child-Completed, 4 Items): The child responds to 4 pictorial questions featuring cartoon faces depicting symptom severity (0 to 3 scale: 0 = worst/frowning face, 3 = best/smiling face) assessing feeling, coughing, waking up at night, and daytime limitations.
Part 2 (Parent/Caregiver-Completed, 3 Items): The caregiver responds to 3 questions on a 0 to 5 Likert scale evaluating daytime wheeze, daytime cough, and nighttime waking.
Scoring & Interpretation (Range: 0 to 27):
20 to 27: Well Controlled asthma.
≤19: Uncontrolled (Poorly Controlled) asthma.
3. Asthma Control Questionnaire (ACQ)
Developer: Dr. Elizabeth Juniper.
Target Population: Adults and children aged 6 years and older.
Recall Window: Past 1 week (7 days).
Structure: Available in several validated formats:
ACQ-7 (Full Version): 5 symptom items (night waking, morning symptoms, activity limitation, shortness of breath, wheezing) + SABA use + FEV1 % predicted (measured by spirometry).
ACQ-6: 5 symptom items + SABA use (without spirometry).
ACQ-5: 5 symptom items alone (ideal for epidemiological research or telephone screening).
Scoring & Interpretation (Range: 0.0 to 6.0): Items are scored from 0 (totally controlled) to 6 (severely uncontrolled). The final score is the mean (average) of all item responses.
≤0.75: Well Controlled asthma.
0.76 to 1.49: "Grey Zone" (Indeterminate Control) —the patient is neither clearly well controlled nor clearly uncontrolled.
≥1.50: Poorly Controlled (Inadequately Controlled) asthma.
Minimal Clinically Important Difference (MCID): 0.5 points . A change of ≥0.5 indicates a clinically meaningful shift.
4. Asthma Therapy Assessment Questionnaire (ATAQ)
Structure: 20-item disease-management survey containing a 4-item self-administered Asthma Control Domain (assessing missed work/school, nocturnal awakenings, SABA use during physical activity, and perception of control).
Scoring: Scored from 0 to 4 based on the number of affirmative responses indicating control problems (0 = No control problems; 1–2 = Low to medium control problems; 3–4 = High control problems).
Comparison of Validated Asthma Control Questionnaires
Instrument Target Age Cohort Recall Period Number of Items Scoring Methodology & Range Uncontrolled Cutoff Threshold Minimal Clinically Important Difference (MCID)
Asthma Control Test (ACT) ≥12 years & adults Past 4 weeks 5 items Sum of scores (5 to 25 points) Score ≤19 3.0 points
Childhood ACT (c-ACT) 4 to 11 years Past 4 weeks 7 items (4 child + 3 parent) Sum of scores (0 to 27 points) Score ≤19 3.0 points
Asthma Control Questionnaire (ACQ) ≥6 years & adults Past 1 week 5, 6, or 7 items Mean average of items (0.0 to 6.0) Score ≥1.50 (≤0.75 is well controlled) 0.5 points
Asthma Therapy Assessment Questionnaire (ATAQ) All ages (parent proxy <18) Past 4 weeks 4 control items Sum of positive risk indicators (0 to 4) Score ≥1 (Score 3–4 indicates high risk) Not formally defined as numeric scale
Clinical Action Triggers: Stepping Therapy Up or Down
Assessing control directly triggers clinical action according to the EPR-3 and GINA step-wise algorithms: Clinical Management Algorithm Based on Assessed Control:
- ┌───────────────────────────┬───────────────────────────────────────────────────────────────┐
- │ Control Level │ Recommended Action & Follow-Up │
- ├───────────────────────────┼───────────────────────────────────────────────────────────────┤
- │ Well Controlled │ • Maintain current pharmacotherapy. │
- │ (ACT ≥20, ACQ ≤0.75) │ • Follow up in 1 to 6 months. │
- │ │ • Consider STEPPING DOWN if well controlled for ≥3 months. │
- ├───────────────────────────┼───────────────────────────────────────────────────────────────┤
- │ Not Well Controlled │ • STEP UP by 1 step. │
- │ (ACT 16–19, ACQ 0.76–1.49)│ • Re-evaluate in 2 to 6 weeks. │
- │ │ • Before stepping up: Check technique, adherence, triggers! │
- ├───────────────────────────┼───────────────────────────────────────────────────────────────┤
- │ Very Poorly Controlled │ • Consider short course of Oral Systemic Corticosteroids. │
- │ (ACT ≤15, ACQ ≥1.50) │ • STEP UP by 1 or 2 steps. │
- │ │ • Re-evaluate in 2 weeks. │
- └───────────────────────────┴───────────────────────────────────────────────────────────────┘
Essential Educator Rule Before Stepping Up: Prior to escalating pharmacotherapy for a patient who is "Not Well Controlled," the asthma educator must systematically verify four non-pharmacologic determinants:
Inhaler Technique: Are they loading and breathing the device correctly?
Medication Adherence: Are they taking their daily controller as prescribed?
Environmental Trigger Exposures: Has there been new allergen or irritant exposure (e.g., tobacco smoke, new pet)?
Comorbid Conditions: Are untreated rhinitis, sinusitis, GERD, or obstructive sleep apnea exacerbating symptoms?